Genetic and epigenetic-sensitive regulatory network in immune response: a putative link between HLA-G and diabetes
| Autor: | Sommese L, Benincasa G, Schiano C, Marfella R, Grimaldi V, Sorriento A, Lucchese R, Fiorito C, Sardu C, Nicoletti GF, Napoli C., SCHIANO, Concetta |
|---|---|
| Přispěvatelé: | Sommese, L, Benincasa, G, Schiano, C, Marfella, R, Grimaldi, V, Sorriento, A, Lucchese, R, Fiorito, C, Sardu, C, Nicoletti, Gf, Napoli, C., Schiano, Concetta |
| Rok vydání: | 2019 |
| Předmět: |
Network medicine
Candidate gene Endocrinology Diabetes and Metabolism HLA-G Coronary Disease 030209 endocrinology & metabolism Human leukocyte antigen Bioinformatics polymorphism Epigenesis Genetic 03 medical and health sciences 0302 clinical medicine Gene Frequency Downregulation and upregulation Diabetes mellitus Diabetes Mellitus medicine Humans Genetic Predisposition to Disease Epigenetics 3' Untranslated Regions Genetic Association Studies network medicine HLA-G Antigens Polymorphism Genetic business.industry medicine.disease diabete inflammation 030220 oncology & carcinogenesis business epigenetic DNA hypomethylation |
| Zdroj: | Expert Review of Endocrinology & Metabolism. 14:233-241 |
| ISSN: | 1744-8417 1744-6651 |
| DOI: | 10.1080/17446651.2019.1620103 |
| Popis: | Introduction: Human leukocyte antigen-G (HLA-G) gene encodes for a tolerogenic molecule constitutively expressed in human pancreas and upregulated upon inflammatory signals. The 14 bp INS/DEL polymorphism in the 3ʹUTR of HLA-G may influence the susceptibility for diabetes and coronary heart diseases (CHD), thus suggesting a novel candidate gene. DNA hypomethylation at HLA-G promoter may be a putative useful clinical biomarker for CHD onset. Upregulation of soluble HLA-G isoform (sHLA-G) was detected in prediabetic and diabetic subjects, suggesting a putative role in metabolic dysfunctions. Areas covered: We conducted a scoping literature review of genetic and epigenetic-sensitive mechanisms regulating HLA-G in diabetes. English-language manuscripts published between 1997 and 2019, were identified through PubMed, Google Scholar, and Web of Science database searches. After selecting 14 original articles representing case-control studies, we summarized and critically evaluated their main findings. Expert commentary: Although epigenetic modifications are involved in the onset of hyperglycemic conditions evolving into diabetes and CHD, it is still difficult to obtain simple and useful clinical biomarkers. Inflammatory-induced KDM6A/INF-β/HLA-G axis might be a part of the epigenetic network leading to overexpression of HLA-G at pancreatic level. Network medicine may show whether HLA-G is involved in diabetes and CHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|